secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2021-10-14T23:59:59+00:00
Accession:  0001193125-21-298277
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics appoints Brendan Smith as CFO; Michael Tomsicek retires
---------------------------------------------------------------------------

- Brendan Smith named SVP & CFO effective Oct 14, 2021; succeeds Michael Tomsicek who retired.
- Smith previously CFO at Translate Bio (acquired by Sanofi for $3.2B) and partner at BCG.
- Smith receives $435K base salary, 40% bonus target, 90K options and 15K RSUs with standard vesting.
- Tomsicek to remain in advisory role through Dec 31, 2021; his departure not due to any accounting disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000119312521298277/0001193125-21-298277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000119312521298277/d212374d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-298277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer